Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2176160 | 1.00 | L3MBTL1 (0.50) | L3MBTL1MTNR1AMTNR1BAKR1C3AKR1C2 | |
| SCHEMBL2322439 | 1.00 | L3MBTL1 (0.50) | L3MBTL1MTNR1AMTNR1BAKR1C3AKR1C2 | |
| SCHEMBL2178238 | 1.00 | L3MBTL1 (0.50) | L3MBTL1MTNR1AMTNR1BAKR1C3AKR1C2 | |
| SCHEMBL30786879 | 1.00 | L3MBTL1 (0.50) | L3MBTL1MTNR1AMTNR1BAKR1C3AKR1C2 | |
| SCHEMBL13730285 | 0.92 | L3MBTL1 (0.47) | L3MBTL1MTNR1AMTNR1BPTGS1FFAR1 | |
| SCHEMBL2180325 | 0.87 | L3MBTL1 (0.49) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL2154692 | 0.87 | L3MBTL1 (0.49) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL2180203 | 0.87 | L3MBTL1 (0.49) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL2154689 | 0.87 | L3MBTL1 (0.49) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL13731760 | 0.87 | L3MBTL1 (0.56) | L3MBTL1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117230124-A | Preparation method of tapentadol chiral intermediate | 天津法莫西生物医药科技有限公司 | 2023-12-15 | — | — | CN | claimed |
| CN-117230124-A | Preparation method of tapentadol chiral intermediate | 天津法莫西生物医药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-2617706-B1 | NOVEL INTERMEDIATE USED FOR PREPARING TAPENTADOL OR ANALOGUES THEREOF | ANHUI NEW STAR PHARMACEUTICAL DEV CO LTD (CN) | 2017-09-06 | — | — | EP | disclosed |
| US-9682918-B2 | intermediate used for preparing tapentadol or analogues thereof | ANHUI NEW STAR PHARMACEUTICAL DEVLOPMENT CO., LTD. (CN) | 2017-06-20 | — | — | US | disclosed |
| US-9556107-B2 | Intermediate used for preparing tapentadol or analogues thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2017-01-31 | — | — | US | disclosed |
| US-20160052873-A1 | Novel Intermediate Used for Preparing Tapentadol or Analogues Thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2016-02-25 | — | — | US | disclosed |
| US-20160052866-A1 | Novel Intermediate Used for Preparing Tapentadol or Analogues Thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2016-02-25 | — | — | US | disclosed |
| US-8853393-B2 | Intermediate for preparing tapentadol or analogues thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2014-10-07 | — | — | US | disclosed |
| US-20130231478-A1 | Novel Intermediate for Preparing Tapentadol or Analogues Thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2013-09-05 | — | — | US | disclosed |
| EP-2617706-A1 | NOVEL INTERMEDIATE USED FOR PREPARING TAPENTADOL OR ANALOGUES THEREOF | Anhui New Star Pharmaceutical Development Co., Ltd (CN) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012146978-A2 | A NOVEL PROCESS FOR THE PREPARATION OF TAPENTADOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2012-11-01 | — | — | WO | disclosed |
| WO-2011092719-A2 | PROCESS FOR THE PREPARATION OF L-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVES | IND-SWIFT LABORATORIES LIMITED (IN) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011080756-A1 | PROCESS FOR THE PREPARATION OF 1-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVES | IND-SWIFT LABORATORIES LIMITED (IN) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052873-A1 | Novel Intermediate Used for Preparing Tapentadol or Analogues Thereof | CYP1A2, CYP7A1, ACHE | L3MBTL1 4401/4885MTNR1A 108/4885MTNR1B 81/4885 |
| US-20130231478-A1 | Novel Intermediate for Preparing Tapentadol or Analogues Thereof | CYP1A2, CYP7A1, CYP3A5 | L3MBTL1 4322/4885MTNR1A 112/4885MTNR1B 91/4885 |
| US-20160052866-A1 | Novel Intermediate Used for Preparing Tapentadol or Analogues Thereof | CYP1A2, CYP7A1, ACHE | L3MBTL1 4401/4885MTNR1A 108/4885MTNR1B 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.